Global Type 1 Diabetes Medicines 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI05241790

Publication Date:

June 5, 2024

Pages:

138

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Type 1 diabetes is a chronic (life-long) autoimmune disease that prevents your pancreas from making insulin. It requires daily management with insulin injections and blood sugar monitoring. Both children and adults can be diagnosed with Type 1 diabetes. Even after a lot of research, type 1 diabetes has no cure. Treatment is directed toward managing the amount of sugar in the blood using insulin, diet and lifestyle to prevent complications.
The global Type 1 Diabetes Medicines market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淭ype 1 Diabetes Medicines Industry Forecast鈥� looks at past sales and reviews total world Type 1 Diabetes Medicines sales in 2022, providing a comprehensive analysis by region and market sector of projected Type 1 Diabetes Medicines sales for 2023 through 2029. With Type 1 Diabetes Medicines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type 1 Diabetes Medicines industry.
This Insight Report provides a comprehensive analysis of the global Type 1 Diabetes Medicines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Type 1 Diabetes Medicines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Type 1 Diabetes Medicines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type 1 Diabetes Medicines and breaks down the forecast by Type, by Channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type 1 Diabetes Medicines.
According to IDF data, in 2022, around 8.75 million people with type 1 diabete. Among them, 1.52 million patients are under 20. People with type 1 diabetes require daily insulin treatment, regular blood glucose monitoring and a healthy lifestyle to manage their condition effectively.
This report presents a comprehensive overview, market shares, and growth opportunities of Type 1 Diabetes Medicines market by product type, application, key players and key regions and countries.
Segmentation by Type:
Insulin
Others
Segmentation by Channel:
Hospital
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Insulin
Others
Segmentation by Channel:
Hospital
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
Bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Wockhardt
Jiangsu Wanbang
Geropharm

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Type 1 Diabetes Medicines 麻豆原创 Size 2019-2030
2.1.2 Type 1 Diabetes Medicines 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Type 1 Diabetes Medicines by Country/Region, 2019, 2023 & 2030
2.2 Type 1 Diabetes Medicines Segment by Type
2.2.1 Insulin
2.2.2 Others
2.3 Type 1 Diabetes Medicines 麻豆原创 Size by Type
2.3.1 Type 1 Diabetes Medicines 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Type 1 Diabetes Medicines 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Type 1 Diabetes Medicines Segment by Channel
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.5 Type 1 Diabetes Medicines 麻豆原创 Size by Channel
2.5.1 Type 1 Diabetes Medicines 麻豆原创 Size CAGR by Channel (2019 VS 2023 VS 2030)
2.5.2 Global Type 1 Diabetes Medicines 麻豆原创 Size 麻豆原创 Share by Channel (2019-2024)
3 Type 1 Diabetes Medicines 麻豆原创 Size by Player
3.1 Type 1 Diabetes Medicines 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Type 1 Diabetes Medicines Revenue by Player (2019-2024)
3.1.2 Global Type 1 Diabetes Medicines Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Type 1 Diabetes Medicines Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Type 1 Diabetes Medicines by Region
4.1 Type 1 Diabetes Medicines 麻豆原创 Size by Region (2019-2024)
4.2 Global Type 1 Diabetes Medicines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Type 1 Diabetes Medicines 麻豆原创 Size Growth (2019-2024)
4.4 APAC Type 1 Diabetes Medicines 麻豆原创 Size Growth (2019-2024)
4.5 Europe Type 1 Diabetes Medicines 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Type 1 Diabetes Medicines 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Type 1 Diabetes Medicines 麻豆原创 Size by Country (2019-2024)
5.2 Americas Type 1 Diabetes Medicines 麻豆原创 Size by Type (2019-2024)
5.3 Americas Type 1 Diabetes Medicines 麻豆原创 Size by Channel (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Type 1 Diabetes Medicines 麻豆原创 Size by Region (2019-2024)
6.2 APAC Type 1 Diabetes Medicines 麻豆原创 Size by Type (2019-2024)
6.3 APAC Type 1 Diabetes Medicines 麻豆原创 Size by Channel (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Type 1 Diabetes Medicines 麻豆原创 Size by Country (2019-2024)
7.2 Europe Type 1 Diabetes Medicines 麻豆原创 Size by Type (2019-2024)
7.3 Europe Type 1 Diabetes Medicines 麻豆原创 Size by Channel (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Type 1 Diabetes Medicines by Region (2019-2024)
8.2 Middle East & Africa Type 1 Diabetes Medicines 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Type 1 Diabetes Medicines 麻豆原创 Size by Channel (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Type 1 Diabetes Medicines 麻豆原创 Forecast
10.1 Global Type 1 Diabetes Medicines Forecast by Region (2025-2030)
10.1.1 Global Type 1 Diabetes Medicines Forecast by Region (2025-2030)
10.1.2 Americas Type 1 Diabetes Medicines Forecast
10.1.3 APAC Type 1 Diabetes Medicines Forecast
10.1.4 Europe Type 1 Diabetes Medicines Forecast
10.1.5 Middle East & Africa Type 1 Diabetes Medicines Forecast
10.2 Americas Type 1 Diabetes Medicines Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Type 1 Diabetes Medicines Forecast
10.2.2 Canada 麻豆原创 Type 1 Diabetes Medicines Forecast
10.2.3 Mexico 麻豆原创 Type 1 Diabetes Medicines Forecast
10.2.4 Brazil 麻豆原创 Type 1 Diabetes Medicines Forecast
10.3 APAC Type 1 Diabetes Medicines Forecast by Region (2025-2030)
10.3.1 China Type 1 Diabetes Medicines 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Type 1 Diabetes Medicines Forecast
10.3.3 Korea 麻豆原创 Type 1 Diabetes Medicines Forecast
10.3.4 Southeast Asia 麻豆原创 Type 1 Diabetes Medicines Forecast
10.3.5 India 麻豆原创 Type 1 Diabetes Medicines Forecast
10.3.6 Australia 麻豆原创 Type 1 Diabetes Medicines Forecast
10.4 Europe Type 1 Diabetes Medicines Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Type 1 Diabetes Medicines Forecast
10.4.2 France 麻豆原创 Type 1 Diabetes Medicines Forecast
10.4.3 UK 麻豆原创 Type 1 Diabetes Medicines Forecast
10.4.4 Italy 麻豆原创 Type 1 Diabetes Medicines Forecast
10.4.5 Russia 麻豆原创 Type 1 Diabetes Medicines Forecast
10.5 Middle East & Africa Type 1 Diabetes Medicines Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Type 1 Diabetes Medicines Forecast
10.5.2 South Africa 麻豆原创 Type 1 Diabetes Medicines Forecast
10.5.3 Israel 麻豆原创 Type 1 Diabetes Medicines Forecast
10.5.4 Turkey 麻豆原创 Type 1 Diabetes Medicines Forecast
10.6 Global Type 1 Diabetes Medicines Forecast by Type (2025-2030)
10.7 Global Type 1 Diabetes Medicines Forecast by Channel (2025-2030)
10.7.1 GCC Countries 麻豆原创 Type 1 Diabetes Medicines Forecast
11 Key Players Analysis
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Type 1 Diabetes Medicines Product Offered
11.1.3 Novo Nordisk Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Type 1 Diabetes Medicines Product Offered
11.2.3 Sanofi Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Sanofi Main Business Overview
11.2.5 Sanofi Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly Type 1 Diabetes Medicines Product Offered
11.3.3 Eli Lilly Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 Merck
11.4.1 Merck Company Information
11.4.2 Merck Type 1 Diabetes Medicines Product Offered
11.4.3 Merck Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Merck Main Business Overview
11.4.5 Merck Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Type 1 Diabetes Medicines Product Offered
11.5.3 AstraZeneca Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Bayer
11.6.1 Bayer Company Information
11.6.2 Bayer Type 1 Diabetes Medicines Product Offered
11.6.3 Bayer Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Bayer Main Business Overview
11.6.5 Bayer Latest Developments
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Information
11.7.2 Boehringer Ingelheim Type 1 Diabetes Medicines Product Offered
11.7.3 Boehringer Ingelheim Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Boehringer Ingelheim Main Business Overview
11.7.5 Boehringer Ingelheim Latest Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Type 1 Diabetes Medicines Product Offered
11.8.3 Johnson & Johnson Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Johnson & Johnson Main Business Overview
11.8.5 Johnson & Johnson Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Type 1 Diabetes Medicines Product Offered
11.9.3 Takeda Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Tonghua Dongbao
11.10.1 Tonghua Dongbao Company Information
11.10.2 Tonghua Dongbao Type 1 Diabetes Medicines Product Offered
11.10.3 Tonghua Dongbao Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Tonghua Dongbao Main Business Overview
11.10.5 Tonghua Dongbao Latest Developments
11.11 United Pharmaceuticals
11.11.1 United Pharmaceuticals Company Information
11.11.2 United Pharmaceuticals Type 1 Diabetes Medicines Product Offered
11.11.3 United Pharmaceuticals Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 United Pharmaceuticals Main Business Overview
11.11.5 United Pharmaceuticals Latest Developments
11.12 Ganli Pharmaceutical
11.12.1 Ganli Pharmaceutical Company Information
11.12.2 Ganli Pharmaceutical Type 1 Diabetes Medicines Product Offered
11.12.3 Ganli Pharmaceutical Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Ganli Pharmaceutical Main Business Overview
11.12.5 Ganli Pharmaceutical Latest Developments
11.13 Biocon
11.13.1 Biocon Company Information
11.13.2 Biocon Type 1 Diabetes Medicines Product Offered
11.13.3 Biocon Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Biocon Main Business Overview
11.13.5 Biocon Latest Developments
11.14 Wockhardt
11.14.1 Wockhardt Company Information
11.14.2 Wockhardt Type 1 Diabetes Medicines Product Offered
11.14.3 Wockhardt Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Wockhardt Main Business Overview
11.14.5 Wockhardt Latest Developments
11.15 Jiangsu Wanbang
11.15.1 Jiangsu Wanbang Company Information
11.15.2 Jiangsu Wanbang Type 1 Diabetes Medicines Product Offered
11.15.3 Jiangsu Wanbang Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Jiangsu Wanbang Main Business Overview
11.15.5 Jiangsu Wanbang Latest Developments
11.16 Geropharm
11.16.1 Geropharm Company Information
11.16.2 Geropharm Type 1 Diabetes Medicines Product Offered
11.16.3 Geropharm Type 1 Diabetes Medicines Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Geropharm Main Business Overview
11.16.5 Geropharm Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.